Clinical Scorecard: Video: Nanotechnology Meets Glaucoma Care
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma |
| Key Mechanisms | Utilizes metamaterial nanotechnology for intraocular pressure control. |
| Target Population | Patients with refractory primary open-angle glaucoma and mild to moderate open-angle glaucoma. |
| Care Setting | Clinical trials and surgical settings. |
Key Highlights
- VisiPlate Aqueous Shunt controls intraocular pressure via microchannel drainage.
- SAPPHIRE study is evaluating VisiPlate in refractory glaucoma patients.
- VisiPlate technology has shown excellent safety and durability in the VITA study.
Guideline-Based Recommendations
Diagnosis
- Evaluate intraocular pressure and visual field loss for glaucoma diagnosis.
Management
- Consider VisiPlate for patients with refractory primary open-angle glaucoma.
Monitoring & Follow-up
- Regular follow-up to assess intraocular pressure and device performance.
Risks
- Potential complications from surgical implantation and device malfunction.
Patient & Prescribing Data
Patients with refractory primary open-angle glaucoma and those undergoing cataract surgery.
VisiPlate and VisiPlate-S are designed to improve IOP control with minimal invasiveness.
Clinical Best Practices
- Utilize biocompatible materials to reduce fibrotic response.
- Engage in interdisciplinary collaboration for technology development.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.